Immunotech Laboratories Founder & Chief Scientific Officer Harry Zhabilov Comments on Recent HIV Baby Cure Medicine
Published: Mar 12, 2013
MONROVIA, CA--(Marketwire - March 12, 2013) - Immunotech Laboratories, Inc. (PINKSHEETS: IMMB) Immunotech Company Founder & Chief Scientific Officer Harry Zhabilov comments on the recent AIDS-HIV Baby Cure Treatments.
Regarding the recently published articles and Media announcements of the HIV case with the newborn baby. This experiment one more time confirms the mechanism of action of chemotherapy of HIV. This means chemotherapy works only when the HIV virus is in the blood stream. When the virus reaches all of the viral reservoirs in the system, it is more difficult for chemotherapy to extract the virus from the viral reservoirs of the blood stream. The treatment appears to have been successful because the virus was already in baby's blood steam the treatment used does not allow the virus to reach the reservoir like monocyte-macrophages, Langerhans cells, follicular-dendritic cells, retinal cells.
By using immunotherapy treatments we are increasing the level of natural killer cells and CD 8 which are responsible for attacking the virus in any corner of the system. This is the reason that chemotherapy has a fast effect under the level of PCR (Polymerase Chain Reaction) whereas; immunotherapy works slowly but does not have resistance.
In a recent article presenting the findings said Dr Deborah Persaud, a virologist at Johns Hopkins University in Baltimore said, "This is a proof of concept that HIV can be potentially curable in infants."
Reuters Mar 4, 2013, 09.43AM. IST "Article Remnant". (Complete article link below)
Because of her risk, Dr Hannah Gay, a pediatric HIV specialist put the infant on a cocktail of three HIV-fighting drugs -- zidovudine (also known as AZT), lamivudine, and nevirapine -- when she was just 30 hours old. Two blood tests done within the first 48 hours of the child's life confirmed her infection and she was kept on the full treatment regimen, Persaud told reporters at the conference.
In more typical pregnancies, when an HIV-infected mother has been given drugs to reduce the risk of transmission to her child, the baby would only have been given a single drug, nevirapine.
Researchers believe use of the more aggressive antiretroviral treatment when the child was just days old likely resulted in her cure by keeping the virus from forming hard-to-treat pools of cells known as viral reservoirs, which lie dormant and out of the reach of standard medications. These reservoirs rekindle HIV infection in patients who stop therapy, and they are the reason most HIV-infected individuals need lifelong treatment to keep the infection at bay.
RELEVANT ARTICLES & LINKS FOR BABY AIDS-HIV MEDICINE CURES
About Immunotech Laboratories
Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and Aids. www.immunotechlab.com
Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.
The Nabors Group
E-mail: Email Contact